Tumor Cell Vaccine Elicits Potent Antitumor Immunity after Allogeneic T-Cell-depleted Bone Marrow Transplantation

摘要: Allogeneic bone marrow transplantation (BMT) is currently restricted to hematological malignancies because of a lack antitumor activity against solid cancers. We have tested novel treatment strategy stimulate specific tumor after BMT by vaccination with irradiated cells engineered secrete granulocyte-macrophage colony-stimulating factor (GM-CSF). Using the B16 melanoma model, we found that elicited potent in recipients syngeneic time-dependent fashion, and immune reconstitution was critical for development activity. Vaccination did not immunity allogeneic post-BMT immunodeficiency associated graft-versus-host disease (GVHD). Remarkably, effective stimulating long-lasting T-cell-depleted (TCD) marrow. Recipients TCD who showed significant 6 weeks developed B16-specific T-cell-cytotoxic, proliferative, cytokine responses as function vaccination. T derived from donor stem were, therefore, able recognize antigens, although they remained tolerant host histocompatibility antigens. These results demonstrate GM-CSF-based cell vaccines can effects without induction GVHD, this has important implications patients malignancies.